The KRT7 expression on benign cores from prostate biopsies could help segregate patients and recommend low-KRT7 patients for active surveillance, while proposing radical treatment to high-KRT7 patients (MFI of KRT7 > 80th percentile) due to a higher risk of the onset of bone metastasis. Here, KRT7 is linked to bone metastasis.